21st Century Oncology to join Australia’s GenesisCare in a partnership to increase access to high quality cancer care in U.S. communities

FLORIDA, U.S. – Cancer patients in communities across the U.S. are expected to benefit from increased access to high quality cancer care, with U.S. provider of radiation therapy and integrated cancer treatments, 21st Century Oncology, to become part of Australian cancer and cardiac care company, GenesisCare.

The combined experience and reach of 21st Century Oncology’s specialists from the U.S., coupled with GenesisCare’s network across Australia and Europe, is expected to better enable global best practice in treatment techniques and evidenced based care.

The group will be focused on achieving best possible outcomes for patients, supporting doctors and teams, and maintaining the highest standards of patient privacy in each market.

GenesisCare plans to invest an additional US$300m in the U.S. over the next three years. The sizable investment is targeted towards an expansion of treatment options for patients, including installation of state-of-the-art equipment and an expanded clinical footprint.

21st Century Oncology leadership will remain in the U.S. and patients will continue to receive seamless, high quality services in their local communities.

GenesisCare Founder and Chief Executive Officer, Dan Collins, said: “We can achieve much more together than we can apart, and are proud to be bringing together 21st Century Oncology’s leading network of integrated cancer care physicians and GenesisCare’s highly experienced clinical specialists. Together, our goal is to increase patient access to high quality cancer care in communities across the U.S.”

The acquisition marks another landmark step in GenesisCare’s international expansion and 21st Century Oncology’s 30-year history.

GenesisCare traces its origins to a single clinic in Brisbane, Australia, which over 15 years has grown to become the largest provider of cancer care services in Australia and Europe. The organization enjoys a proven track record of increasing patient satisfaction, reducing treatment and wait times, and making it easier and cheaper for patients to access advanced treatment techniques in the markets it services.

As part of the combination, 21st Century Oncology’s 124 radiation oncology treatment centers and 170 clinical offices, which provide integrated cancer care services, in the U.S., will join GenesisCare’s collaborative network. In combination, this completes a global network of almost 200 radiation oncology treatment centers and 170 clinical offices.

“We are excited to collaborate with 21st Century Oncology to expand our reach in a significant new market for GenesisCare and bring U.S. patients the benefits of one of the largest, high quality cancer care networks in the world,” Mr Collins said.

21st Century Oncology Chief Executive Officer, Kim Commins-Tzoumakas, welcomed the collaboration.

“We sought to find the best partner to take the next step with us in growing and improving the premier integrated cancer care network we have built in the United States,” Ms. Commins-Tzoumakas said.

“We are confident that we have found that partner in GenesisCare to bring together the right resources, world-class medical professionals and the innovative technology required to provide the best medical care and advancements to our patients and those who support them.”

GenesisCare continually advances services by adopting the latest clinical guidelines and using real world evidence to refine the treatment process. Central to the company’s patient-centric mission is the adoption of new treatment techniques, the use of advanced technology and conducting research and clinical trials that put the patient first.

The announcement of this transaction comes in the same year as GenesisCare welcomed new Board Chair, Dr Brian McNamee, who is also Chair of the Board at global biotech company CSL.

GenesisCare founder Dan Collins, who established the organization in 2004, continues to lead the company as GenesisCare’s global CEO.

The sale of 21st Century Oncology is subject to customary regulatory reviews and is expected to close by mid 2020.

Related articles

Do you have a question about continuing cancer care safely during Covid-19?

Diagnostic and advanced radiotherapy for prostate cancer

Dave’s 155 mile cycle for Penny Brohn UK

Stereotactic Ablative Radiotherapy (SABR) – an alternative to surgery